Effects on muscle pain by intramuscular injection of granisetron in patients with fibromyalgia

Pain

Volumn 101, Issue 3, 2003, Pages 275-282

  Ernberg, Malin ^a   Lundeberg, Thomas ^a   Kopp, Sigvard ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

5 HT; 5 HT antagonist; Double blind method; Fibromyalgia; Pain threshold; Visual analog pain scale

Indexed keywords

GRANISETRON; ISOTONIC SOLUTION; SEROTONIN 3 ANTAGONIST; SODIUM CHLORIDE;

ADULT; ALLODYNIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FIBROMYALGIA; HUMAN; HYPERALGESIA; MASSETER MUSCLE; MYALGIA; PAIN ASSESSMENT; PAIN THRESHOLD; PRESSURE; PRIORITY JOURNAL;

EID: 0037316617     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3959(02)00334-2     Document Type: Article

References (31)

1. Candito M., Souetre E., Iordache A., Pringuey D., Ardisson J.L., Chambon P., Darcourt G. Diurnal variation in total plasma tryptophan in controls and in depression. J Psychiatr Res. 24:1990;227-230.
2. Chapman C.R. The perception of noxious events. Sternbach R.A. The psychology of pain. 1978;169-203 Raven Press, New York, NY.
3. De Stefano R., Selvi E., Villanova M., Frati E., Manganelli S., Franceschini E., Biasi G., Marcolongo R. Image analysis quantification of substance P immunoreactivity in the trapezius muscle of patients with fibromyalgia and myofascial pain syndrome. J Rheumatol. 27:2000;2906-2910.
4. Eide P.K., Hole K. The role of 5-hydroxytryptamine (5-HT) receptor subtypes and plasticity in the 5-HT systems in the regulation of nociceptive sensitivity. Cephalalgia. 13:1993;75-85.
5. Eriksson P.O., Lindman R., Stal P., Bengtsson A. Symptoms and signs of mandibular dysfunction in primary fibromyalgia syndrome (PSF) patients. Swed Dent J. 12:1988;141-149.
6. Ernberg M., Hedenberg-Magnusson B., Alstergren P., Kopp S. The level of serotonin in the superficial masseter muscle in relation to local pain and allodynia. Life Sci. 65:1999;313-325.
7. Ernberg M., Voog U., Alstergren P., Lundeberg T., Kopp S. Plasma and serum serotonin levels and their relationship to orofacial pain and anxiety in fibromyalgia. J Orofac Pain. 14:2000;37-46.
8. Ernberg M., Lundeberg T., Kopp S. Effect of propranolol and granisetron on experimentally induced pain and allodynia/hyperalgesia by intramuscular injection of serotonin into the human masseter muscle. Pain. 84:2000;339-346.
9. Ernberg M., Lundeberg T., Kopp S. Pain and allodynia/hyperalgesia induced by intramuscular injection of serotonin in patients with fibromyalgia and healthy individuals. Pain. 85:2000;31-39.
10. Gyermek L. 5-HT3 receptors: pharmacologic and therapeutic aspects. J Clin Pharmacol. 35:1995;845-855.
11. Hedenberg-Magnusson B., Ernberg M., Kopp S. Symptoms and signs of temporomandibular disorders in patients with fibromyalgia and local myalgia of the temporomandibular system. A comparative study. Acta Odontol Scand. 6:1997;344-349.
12. 4 in the human masseter muscle. Acta Odontol Scand. 59:2001;348-355.
13. Hindle A.T. Recent developments in the physiology and pharmacology of 5-hydroxytryptamine. Br J Anaesth. 73:1994;395-407.
14. Hrycaj P., Stratz T., Mennet P., Muller W. Pathogenetic aspects of responsiveness to ondansetron (5-hydroxytryptamine type 3 receptor antagonist) in patients with primary fibromyalgia syndrome - a preliminary study. J Rheumatol. 23:1996;1418-1423.
15. Kosek E., Ekholm J., Hansson P. Sensory dysfunction in fibromyalgia patients with implications for pathogenic mechanisms. Pain. 68:1996;375-383.
16. Krag N.J., Norregaard J., Larsen J.K., Danneskiold-Samsoe B. A blinded, controlled evaluation of anxiety and depressive symptoms in patients with fibromyalgia, as measured by standardized psychometric interview scales. Acta Psychiatr Scand. 89:1994;370-375.
17. Nakamura-Craig M., Gill B.K. Effect of neurokinin A, substance P and calcitonin gene related peptide in peripheral hyperalgesia in the rat paw. Neurosci Lett. 124:1991;49-51.
18. Plesh O., Wolfe F., Lane N. The relationship between fibromyalgia and temporomandibular disorders: prevalence and symptom severity. J Rheumatol. 23:1996;1948-1952.
19. Rollman G.B., Lautenbacher S. Hypervigilance effects in fibromyalgia: pain experience and pain perception. Vaeroy H., Merskey H. Progress in fibromyalgia and myofascial pain. 1993;149-159 Elsevier, Amsterdam.
20. Russell I.J., Orr M.D., Littman B., Vipraio G.A., Alboukrek D., Michalek J.E., Lopez Y., MacKillip F. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum. 37:1994;1593-1601.
21. Russell J. Advances in fibromyalgia: possible role for central neurochemicals. Am J Med Sci. 315:1998;377-384.
22. Saria A., Javorsky F., Humpel C., Gamse R. 5-HT3 receptor antagonists inhibit sensory neuropeptide release from the rat spinal cord. NeuroReport. 1:1990;104-106.
23. Simms R.W. Fibromyalgia is not a muscle disorder. Am J Med Sci. 315:1998;346-350.
24. Staud R., Vierck C.J., Cannon R.L., Mauderli A.P., Price D.D. Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome. Pain. 91:2001;165-175.
25. Svensson E., Holm S. Separation of systemic and random differences in ordinal rating scales. Stat Med. 13:1994;2437-2453.
26. Sörensen J., Bengtsson A., Ahlner J., Henriksson K.G., Ekselius L., Bengtsson M. Fibromyalgia - are there different mechanisms in the processing of pain? A double blind crossover comparison of analgesic drugs. J Rheumatol. 24:1997;1615-1621.
27. Tabona M.V. An overview on the use of granisetron in the treatment of emesis associated with cytostatic chemotherapy. Eur J Cancer. 26:(Suppl 1):1990;S37-S44.
28. Værøy H., Helle R., Forre O., Kass E., Terenius L. Elevated CSF levels of substance P and high incidence of raynaud phenomenon in patients with fibromyalgia: new features for diagnosis. Pain. 32:1988;21-26.
29. Wolfe F., Russell I.J., Vipraio G., Ross K., Anderson J. Serotonin levels, pain threshold, and fibromyalgia symptoms in the general population. J Rheumatol. 24:1997;555-559.
30. Wolfe F., Smythe H.A., Yunus M.B., Bennett R.M., Bombardier C., Goldenberg D.L., Tugwell P., Campbell S.M., Abeles M., Clark P., Fam A.G., Farber S.J., Fiechtner J.J., Franklin C.M., Gatter R.A., Hamaty D., Lessard J., Lichtbroun A.S., Masi A.T., McCain G.A., Reynolds W.J., Romano T.J., Russell I.J., Sheon R.P. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee (see comments). Arthritis Rheum. 33:1990;160-172.
31. Yunus M.B. Towards a model of pathophysiology of fibromyalgia: aberrant central pain mechanisms with peripheral modulation (editorial). J Rheumatol. 19:1992;846-850.